National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 28 of 41
Assessment of a B-Mode Ultrasound Technique for the Measurement of Carotid Artery Intima-Media Thickness
NCT00001904
A Study of the Long-Term Outcomes of HIV-Positive Patients
NCT00000932
Etanercept to Treat Wegener's Granulomatosis
NCT00001901
Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy
NCT00001899
Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults
NCT00110578
Drug Interactions Among Anti-HIV Agents
NCT00001766
The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
NCT00000825
Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection
NCT00001763
Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease
NCT00001765
Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions
NCT00001764
Use of Labeled Glucose to Study Lymphocyte Replication and Survival in HIV-Infected Patients
NCT00001651
Magnetic Resonance Imaging of the Face and Bones
NCT00001762
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
NCT00001761
Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients
NCT00005009
Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals
NCT00001760
Study of Mast Cell Precursors
NCT00001756
Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems
NCT00001097
Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography
NCT00001759
Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates
NCT00031460
Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz
NCT00001758
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
NCT00001757
Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients
NCT00031473
Development of a New HIV Vaccine
NCT00051922
Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children
NCT00000893
Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy
NCT00000883
Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients
NCT00001650
Setting up a Blood Bank for Gene Therapy in HIV-Infected Infants
NCT00000917
Structure of the Herpes Simplex Virus Receptor
NCT00001648
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
NCT00001646
Valaciclovir to Prevent Transmission of Herpes Simplex Virus
NCT00001649
A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART
NCT00000874
White Blood Cell Infusions to Treat HIV Infection
NCT00001647
A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers
NCT00001088
Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection
NCT00001644
The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
NCT00001082
A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)
NCT00000867
Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders
NCT00557895
The Effects of Prednisone on HIV Levels and the Immune System
NCT00000921
Fluconazole Prophylaxis of Thrush in AIDS
NCT00001542
A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements
NCT00001077
Genetic Studies of X-linked Lymphoproliferative Disease
NCT00359411
The Use of Bacteriophage Phi X174 to Assess the Immune Competence of HIV-Infected Patients In Vivo
NCT00001540
Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis
NCT00001541
Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers
NCT00001538
Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
NCT00001477
Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up
NCT00001476
Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist
NCT00001475
Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients
NCT00001474
Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
NCT00001473
Evaluation and Monitoring of Patients With HIV Infectionn
NCT00557570
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.